Clinical evidence has revealed that while RAS/RAF/MEK/ERK pathway is a crucial component of melanomagenesis, other signaling pathways can also contribute to the malignant growth and development of resistance to targeted therapies. We explored the response of V600E BRAF melanoma cells derived from surgical specimens and grown in stem cell medium to vemurafenib and trametinib, drugs targeting the activity of V600E BRAF and MEK1/2, respectively. Cell growth and apoptosis were monitored by real-time imaging system, immunophenotype and cell cycle by flow cytometry, gene expression by quantitative real-time PCR, immunoblotting and enzyme-linked immunosorbent assay. The V600E BRAF melanoma cell populations were diverse. Differences in morphology, pigmentation, cell cycle profiles, and immunophenotype were observed. At the molecular level, melanoma cells differed in the phosphorylation of ERK1/2, NF-κB, and β-catenin, and expression of several relevant genes, including MITF-M, DKK1, CCND1, BRAF, CXCL8, and CTGF. Despite having different characteristics, melanoma cells responded similarly to vemurafenib and trametinib. Both drugs reduced ERK1/2 phosphorylation and percentages of cells expressing Ki-67 at high level, inhibited expression of CCND1 and induced cell cycle arrest in the G o /G 1 phase. These expected cytostatic effects were accompanied by increased CD271 expression, a marker of stem-like cells. NF-κB activity was reduced by both drugs, however, not completely abolished, whereas the level of active β-catenin was increased by drugs in three out of six cell populations. Interestingly, expression of IL-8 and CTGF was significantly reduced by treatment with vemurafenib and trametinib. Simultaneous inhibition of NF-κB activity and induction of ERK1/2 phosphorylation revealed that CTGF expression depends on ERK1/2 activity but not on NF-κB activity. Both, the positive effects of treatment with vemurafenib and trametinib such as the newly identified CTGF suppression and undesired effects such as increased CD271 expression suggesting selection of melanoma stem-like cells should be considered in the development of combination treatment for melanoma patients.
Targeted therapies against elements of the RAF/MEK/ERK pathway have revolutionized the treatment of patients with advanced melanoma prolonging both progression-free and overall survival. [1] [2] [3] The response to treatment, however, is not guaranteed, and off-target effects and acquired resistance are observed in the majority of patients. [4] [5] The varied clinical efficacy achieved in melanoma patients treated with targeted therapies can be explained by phenotypic heterogeneity, plasticity, multicellular complexity, and reciprocal interactions with the microenvironment that are attributed to metastatic melanoma. 5, 6 A better understanding of melanoma response to inhibitors of the BRAF/MEK/ERK pathway is crucial for selecting the most appropriate group of patients for the treatment and developing effective strategies to overcome inherent and acquired resistance.
In the present study, two drugs vemurafenib (PLX4032; Zelboraf), a V600E BRAF inhibitor, and trametinib (GSK1120212; Mekinist), a MEK1/2 inhibitor, were investigated. Both drugs are approved by the US Food and Drug Administration for the treatment of patients with advanced melanoma harboring mutation in BRAF (V600E). Our previous reports indicate that melanoma cells populations derived from surgical specimens and grown in stem cell medium (SCM) better preserve the distinct phenotypic states of melanoma tumors than commercially available cell lines grown as monolayer in serum-containing medium. 7, 8 Therefore, likely they represent a more reliable and clinically relevant model system than do xenograft tumors derived from established melanoma cell lines. A most recently published report that examined distinct phenotypic states of melanoma tumors by a single-cell RNA sequencing indicates that the same tumor sample can exert transcriptional heterogeneity that is associated with the cell cycle and spatial context. 6 Our study is focused on the whole melanoma cell population cultured in vitro as we assume that the interactions between different subpopulations might influence melanoma phenotype and response to drug treatment. [8] [9] [10] Six melanoma cell populations with activating mutation in BRAF (V600E) were used to explore the melanoma response to vemurafenib and trametinib. Cells were extensively investigated to show similarities and differences at the molecular and cellular levels. Having well characterized cell populations and their targeted response to vemurafenib and trametinib, we have focused on drug-induced alterations in cell composition, particularly CD271 high stem-like cells [11] [12] [13] vs Ki-67 high proliferating cells. In addition, the influence of the drugs on key components of other than RAF/MEK/ERK signaling pathway, namely NF-κB and β-catenin signaling, was investigated at the molecular level. MITF-M, a transcription factor crucial for melanocyte differentiation and melanoma maintenance, [14] [15] [16] DKK1 , an inhibitor of the WNT/β-catenin pathway, 17 whose expression is strongly reduced in melanoma cells compared with melanocytes, 7, 18 CTGF (CCN2) recently considered as a therapeutic target for metastatic melanoma 19 and interleukin 8 (IL-8, encoded by CXCL8), which exhibits significant overexpression in melanoma 20 were investigated among others.
MATERIALS AND METHODS Drugs
Parthenolide was purchased from Biomol (Exeter, UK), vemurafenib and trametinib from Selleck Chemicals LLC (Houston, TX, USA).
Tumor Tissues and Cell Culture
Melanoma cell populations from drug-naive patients were investigated. The study was approved by Ethical Commission of Medical University of Lodz. Informed consent was obtained from all patients. Tumor tissues were processed immediately after surgical procurement and suspensions of melanoma cells for culturing were generated within 2 h. Cells harboring mutation V600E BRAF that were successfully propagated were named DMBC11, DMBC12, DMBC21, DMBC28, DMBC29, and DMBC33 (Department of Molecular Biology of Cancer, DMBC). Melanoma cells were maintained in SCM as described previously. 21 For experiments, melanoma cells were left to grow overnight before being treated with 10 μM vemurafenib or 50 nM trametinib. Then, cells were collected for RNA isolation (after 24 h), protein lysates (after 44 h), cell cycle and immunophenotype analysis (after 44 h). Culture medium was frozen for the IL-8 secretion analysis. Transfection of melanoma cells with specific CTGF siRNA or control siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed by using AMAXA NHEM-Neo Nucleofector Kit and Nucleofector 2b device (Lonza, Basel, Switzerland) according to the manufacturer's protocol. Melanoma cells were collected for cell lysate preparation 24 h after transfection. Human full-length CTGF recombinant protein, purchased from PeproTech Inc (Rocky Hill, NJ, USA), was used at 250 ng/ml for 24 h. Parthenolide and trametinib were used alone or in combination at indicated concentrations, and RNA was isolated after 6 h and cell lysates were prepared after 4 h of incubation.
Microscopy
Changes in cell morphology were registered with a digital Olympus camera (C-5050) attached to Olympus microscope (CKX41, Olympus, London, UK).
A Time-Lapse Fluorescence Microscopy
For cell proliferation, apoptosis and CFSE analysis, a timelapse fluorescence microscope system (IncuCyte, Essen Bioscience) was used. The data were analyzed using IncuCyte Zoom original software. Proliferation was assessed as changes in the area occupied by melanoma cells in control, vehicletreated (0.1% DMSO) and drug-treated cultures (% of confluence) over time. For apoptosis assay, melanoma cells were seeded in 96-well plates at 8 × 10 3 cells/well with IncuCyte Caspase-3/7 Apoptosis Assay Reagent at 4 μM and exposed to 10 μM vemurafenib, 50 nM trametinib or vehicle for 3 days. Activation of caspase-3/7 was monitored every 3 h using live-cell imaging and quantified using the IncuCyte ZOOM basic analyzer. It was expressed as the percentage of confluence of apoptotic cells divided by the percentage of confluence of all cells. For CFSE analysis, melanoma cells were stained with 1.5 μM CFSE (carboxyfluorescein diacetate succinimidyl ester) for 30 min at 37°C, washed twice, seeded in 12-well plates at 1.25 × 10 5 cells/well and exposed to 10 μM vemurafenib, 50 nM trametinib or vehicle for 5 days. Changes in green fluorescence emission were monitored every 6 h. Percentages of label retaining cells were calculated in the same way as percentages of apoptotic cells, however, the thresholds were set at very low levels to filter out non-fluorescent cells.
Acid Phosphatase Activity Assay Doubling time was calculated based on the colorimetric measurement of acid phosphatase activity. 21 Briefly, melanoma cells (4 × 10 3 ) were grown for 24 h and 48 h, then the plates were centrifuged and medium was replaced with assay buffer containing 0.1 mmol/dm 3 of sodium acetate pH = 5, 0.1% Triton X-100 and 5 mmol/dm 3 p-nitrophenyl phosphate (Calbiochem, Darmstadt, Germany). After 2 h of incubation, the reaction was inhibited by 1 mmol/dm 3 NaOH, and the absorbance was measured at 405 nm using microplate reader Infinite M200Pro (Tecan, Salzburg, Austria). The doubling time was calculated using the formula DT = (t -t 0 )log2 / (logA -logA 0 ), in which t and t 0 are the time points at which the cells were collected and A and A 0 are the absorbance values at times t and t 0 , respectively.
Flow Cytometry
Melanoma cells were left to grow overnight before being treated with drugs for 44 h. After treatment, 70% of cells were immunophenotyped and 30% were used for cell cycle analysis. In immunophenotype analysis, isotype controls were included in each experiment. To exclude dead cells from the analysis, LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies, Eugene, OR, USA) was used. Antibodies against CD271 (PE-conjugated) and Ki-67 (Alexa Fluor 647-conjugated) were from BD Pharmingen (San Jose, CA, USA). For intracellular staining, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 20 min. Flow cytometric data were acquired with FACSVerse (BD Biosciences, San Jose, CA, USA), and analyzed using BD FACSuite. For cell cycle analysis, PI/RNase Staining Buffer (BD Pharmingen) was used. ModFit LT 3.0 software was used to calculate the percentages of cells in each cell cycle phase.
RNA Isolation, cDNA Synthesis, and Quantitative RT-PCR (qRT-PCR) Total RNA was isolated and purified using Total RNA Isolation kit with mini column system (A&A Biotechnology, Gdynia, Poland). Total RNA (1 μg) was transcribed into cDNA using 300 ng of random primers and SuperScript II Reverse Transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA). The evaluation of mRNA expression of selected genes was performed by quantitative real-time polymerase chain reaction using the Rotor-Gene 3000 RealTime DNA analysis system (Corbett Research, Morklake, Australia). Amplification was performed using KAPA SYBR FAST qPCR Kit Universal 2X qPCR Master Mix (Kapa Biosystems, Cape Town, South Africa), 200 nM of each primer and 25 ng cDNA template per reaction. Primer sequence for BRAF was: 5′-TCTTTCCCCAAATTCTCGCCT-3′ (forward) and 5′-TCAGTGGACAGGAAACGCAC-3′ (reverse). Sequences of other primers used in qRT-PCR were shown elsewhere. 7, [22] [23] [24] To calculate the relative expression of target genes vs a reference gene RPS17, a mathematical model including an efficiency correction was used.
Western Blots
Melanoma cells were lysed in RIPA buffer containing 50 mmol/l Tris-HCl pH 8.0, 150 mmol/l NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS supplemented with freshly added protease and phosphatase inhibitors (Sigma-Aldrich). Cell lysates were diluted in 2 × Laemmli buffer and protein samples (15 μg each) were loaded on 7% SDS-polyacrylamide gel. The proteins were transferred onto an Immobilon-P PVDF membrane (Millipore, Billerica, MA, USA). The membrane was incubated in a blocking solution: 5% nonfat milk in PBS-Tween 0.05% or 5% phospho-BLOCKER (Cell Biolabs, San Diego, CA, USA) in PBS-Tween 0.05%. Primary antibodies detecting PARP and total β-catenin were from Santa Cruz Biotechnology, active β-catenin (dephosphorylated on Ser 37 V600E BRAF from Biomol (Malvern, PA, USA). Immunodetection of β-actin (SigmaAldrich) was used as a loading control.
Enzyme-Linked Immunosorbent Assay (ELISA) ELISA kit Quantikine High Sensitivity Human CXCL8/IL-8 (R&D Systems, Minneapolis, MN, USA) was used to determine IL-8 secretion to the culture medium by melanoma cells, and was performed according to the manufacturer's instructions. The optical density of each well was determined using a microplate reader Infinite M200Pro (Tecan). Concentrations of IL-8 in the medium samples were obtained by using a four parameter logistic (4-PL) curve fit.
Statistical Analysis
Data show the mean of at least three independent experiments ± s.d. unless stated otherwise. Statistically significant results were considered at *Po0.05.
RESULTS

The Phenotype of Melanoma Cell Populations Derived from Surgical Specimens and Grown in SCM is Diverse
Six melanoma cell populations derived from surgical specimens and designated DMBC11, DMBC12, DMBC21, DMBC28, DMBC29, and DMBC33 were used in this study. All of them harbor mutation in BRAF resulting in a high level of active V600E BRAF kinase as shown for DMBC28, DMBC29, and DMBC33 cells (Figure 1a ) or published previously for other cell lines. 10 They showed different morphology ( Figure 1a ) when grown in SCM. DMBC11, DMBC12, and DMBC33 remained floating as single cells or cell aggregates. DMBC21, DMBC28, and DMBC29 represented 'semi-adherent' cultures, in which both floating and adherent cells were observed. MITF-M was expressed in DMBC21, DMBC28, DMBC29 and DMBC33 cells at a very high level ( Figures 1a  and d) ; however, only one cell population DMBC33 was highly pigmented (Figure 1a ). Cell cycle analysis revealed that DMBC11, DMBC12, and DMBC28 cell populations were fast-cycling, whereas in other cell lines more cells were accumulated in G o /G 1 phase with the highest percentage of G o /G 1 phase-arrested cells in DMBC33 population (Figure 1b) . Accordingly, the highest doubling time, 107.7 h, was observed in DMBC33 population, the lowest, 17.6 h and 18.8 h in DMBC11 and DMBC12, respectively.
Analysis of cell functionality indicated that DMBC12 and DMBC33 cell lines had elevated levels of phosphorylated ERK1/2 in comparison with other cell lines ( Figure 1c ). DMBC33 cells exerted a high level of active β-catenin and the highest activity of NF-κB assessed as phosphorylation of p65 (Figure 1c ), but other cell populations also showed constitutive activity of this transcription factor. A few genes were then chosen to assess their transcript levels (Figure 1d) . CCND1, CXCL8, and BRAF were expressed at much higher levels in the DMBC33 cell lines than in other cell lines, which together with the highest ERK1/2 activity might reflect the hyperactivity of the RAS/RAF/MEK/ERK pathway in this cell line. The MITF-M high cells, DMBC21, DMBC28, DMBC29, and DMBC33 expressed CTNNB1, LEF1, and CTGF at higher levels than MITF-M low cells, whereas DKK1, the inhibitor of the WNT/β-catenin pathway, was expressed at a high level in MITF-M low cells, DMBC11 and DMBC12. Thus, the investigated melanoma cell lines while all harboring V600E BRAF, show diverse phenotypes as the result of various activity of the major signaling pathways (summarized in Table 1 ). Lack of consistency between different features Figure 1a) . This can be explained only as inherent phenotypic heterogeneity of DMBC33 population. DMBC12 cell population was less phenotypically heterogeneous as for example high activity of ERK1/2 was accompanied by a high cell cycling rate and percentage of cells expressing Ki-67 at high level (Supplementary Figure 1a) .
Cytostatic Effects of Vemurafenib and Trametinib Driven by Inhibition of the BRAF/MEK/ERK Pathway were Validated at the Cellular and Molecular Level
First, all cell populations were investigated whether they responded to vemurafenib and trametinib. Concentrations of drugs, 10 μM for vemurafenib and 50 nM for trametinib, were then chosen based on their similar cytostatic effects observed in live-cell time-lapse imaging system IncuCyte (Figure 2a) . The targeted activity of vemurafenib and trametinib was validated by Western blotting. The ERK1/2 activity was abolished after 4 h of treatment (not shown) and was still inhibited after 2 additional days of incubation with either drug (Figure 2b ). This was accompanied by cell cycle arrest in G o /G 1 phase (Figure 2c ). The level of cyclin D1 transcript was also significantly diminished in all cell populations, especially in DMBC33 (Figure 2d) , which exerted the highest basal level of CCND1 expression (Figure 1e) . We also observed a strong influence of vemurafenib and trametinib on the fraction of cells expressing Ki-67 at high level across all investigated melanoma cell populations (Figure 3b ). When apoptosis was assessed by measuring changes in the percentages of cells with high activity of caspase 3/7, only DMBC33 cells did not develop apoptotic cell death response to drug treatment during 72 h of incubation (Figure 2e ). PARP cleavage confirmed these results (Figure 2f ).
Cytostatic Effects of Vemurafenib and Trametinib are
Accompanied by Increased Percentages of Slow-Dividing Cells and Elevated Expression of CD271 Next, to investigate a drug influence on slow-dividing cells time-lapse microscopy was used to measure the retention of CFSE in real time. CFSE is a prodrug for an intracellular green-fluorescent dye that is partitioned evenly between daughter cells upon cell division without causing reduction of cell viability. Over the course of 5 days, untreated cells or cells treated with vehicle diluted out CFSE and decreased in fluorescence intensity more efficiently than vemurafenib-or trametinib-treated cells. DMBC33 cell population was the most efficient in retaining a fluorescence label, which was further enhanced by drug treatment (Figure 3a ). All these results might be explained as cytostatic effects of vemurafenib Figure 3b and Supplementary Figure 1a) were accompanied with increased expression of CD271 and mutually exclusive expression of CD271 and Ki-67 (CD271 high /Ki67 low ) (Figure 3c ), all this suggests that the fraction of more primitive, slow-cycling cells remained less affected by the drug treatment. Vemurafenib/trametinib affect CTGF and IL-8 ML Hartman et al NF-κB and β-Catenin Activities are Only Slightly Affected by Vemurafenib and Trametinib but IL-8 and CTGF Expression is Significantly Reduced by these Drugs Next, the influence of vemurafenib and trametinib on other pathways than RAF/MEK/ERK signaling was investigated (Figure 4a ). The activity of the WNT/β-catenin pathway, which was assessed as the level of active, dephosphorylated β-catenin, was elevated especially in DMBC12 and DMBC21 cells but it remained unchanged in DMBC33 cell population (Figure 4a) , in which the WNT/β-catenin pathway was already highly active ( Figure 1c) . The activity of NF-κB was reduced by both drugs, however, not completely abolished (Figure 4a ). The expression of an NF-κB-dependent gene, CXCL8 was significantly reduced by vemurafenib and trametinib (Figure 4b) , and the secretion of IL-8 into the culture medium was also lowered (Figure 4c ). The strongest reduction of the IL-8 production was observed in DMBC33 cell culture, in which the average secretion of IL-8 was also the highest in untreated culture (1272 pg IL-8/10 5 cells). Besides CXCL8, whose expression was most strongly affected, also expression of CTGF was significantly (Po0.05) downregulated by vemurafenib and trametinib in all investigated melanoma cell populations (Figure 4b) . V600E BRAF/MEK inhibition did not substantially change expression of MITF-M, CTNNB1, DKK1, MMP9, LEF1, and BRAF at transcript levels as assessed by qRT-PCR (Supplementary Figure 1b) .
CTGF Expression Depends on ERK1/2 Activity
As CTGF transcript level was reduced by vemurafenib and trametinib, we hypothesized that CTGF expression might be ERK1/2-dependent. It could be also NF-κB-dependent as the activity of this transcription factor was also diminished by both drugs. To distinguish between these two possibilities, parthenolide was used. As recently shown by our laboratory this compound, known mainly as an NF-κB inhibitor, efficiently increases ERK1/2 activity. 10 Thus, by using parthenolide it was possible to block NF-κB activity and increase ERK1/2 activity at the same time. And indeed immunoblots revealed a dramatic increase in the level of phosphorylated ERK1/2 already after 4 h of incubation, whereas the level of phosphorylated p65 was substantially reduced (Figure 5a ). These effects were accompanied by a significant increase in CTGF transcript level as shown for DMBC21, DMBC29 and DMBC33 cells (Figure 5b ) indicating that CTGF expression might depend on ERK1/2 activity but not on NF-κB activity. CTGF expression was even more enhanced in DMBC11 and DMBC12 reaching a 7.6-fold ± 4.0 and 21.2-fold ± 3.3 increase in comparison to untreated cells, respectively (Supplementary Figure 2a) , but of note the basal level of CTGF transcript was very low in those cells (Figure 1d ). When parthenolide was combined with trametinib, the CTGF transcript level was not significantly changed when compared with its level in untreated cells. As CTGF expression was Figure 2b) , indicating that AP-1 did not contribute to ERK1/2-induced upregulation of CTGF expression. Next, we performed mRNA decay assay. We demonstrated that CTGF transcript stability was not substantially altered in the presence of vemurafenib or trametinib (Supplementary Figure 2c) . We also determined the consequences of changing the level of CTGF on ERK1/2 activity. In the first approach, CTGF expression was blocked with siRNA. A direct blockade of CTGF expression did not result in substantial changes of ERK1/2 phosphorylation as shown for CTGF high p-ERK1/2 low DMBC21 cells and CTGF high p-ERK1/2 high DMBC33 cells ( Figure 5c ). As a second approach, we checked whether exogenous CTGF can change the phosphorylation of ERK1/2 and p65 subunit of NF-κB. Exogenous CTGF neither induced ERK1/2 activity nor prevented its inhibition by vemurafenib and trametinib as shown for p-ERK1/2 high DMBC33 cells (Figure 5d ). No induction of ERK1/2 phosphorylation was also observed in p-ERK1/2 low DMBC21 and DMBC29 cells (Figure 5d ). The exogenous CTGF also did not substantially change the phosphorylation of p65 (Figure 5d ). Therefore, it is reasonable to conclude that CTGF does not markedly influence the RAF/MEK/ERK and NF-κB signaling pathways.
DISCUSSION
The inhibitors of V600E BRAF and MEK1/2 have brought major improvements in blocking constitutively active RAF/MEK/ ERK pathway that is critical for melanoma development. As the RAF/MEK/ERK pathway is strongly connected with other signaling pathways, both its hyperactivation observed in cancer and its inhibition by targeted treatment can induce a plethora of consequences at the molecular and cellular levels. 25 The major and desired effect of using vemurafenib and trametinib in melanoma treatment is the inhibition of cell proliferation and tumor growth. Other consequences of RAF/MEK/ERK inhibition remain largely elusive. Their investigation might bring new directions of studies to overcome intrinsic, adaptive, and acquired resistance.
The complex effects of V600E BRAF and MEK1/2 inhibition presented in this study comprise both positive and negative effects. As previously demonstrated in numerous in vitro and in vivo studies [reviewed in Marzuka et al 26 ] vemurafenib and trametinib strongly inhibited ERK1/2 activity followed by induction of cell cycle arrest in G 0 /G 1 phase. As the consequence of ERK1/2 inhibition, the expression of cyclin D1 was significantly diminished, regardless of its basal level. Apoptosis, which is suppressed by aberrant ERK1/2 activity but is not the major outcome of targeted therapy, 27, 28 was not highly pronounced also in the present study, especially in DMBC33 cell population. It has been demonstrated that Vemurafenib/trametinib affect CTGF and IL-8 ML Hartman et al induction of apoptosis can be inhibited by pretreatment of melanoma cells with LiCl, a β-catenin stabilizing agent, and β-catenin can attenuate vemurafenib efficacy and mediate acquired resistance. 29 Our results showing an elevated level of active β-catenin in cell population not responding with apoptosis to vemurafenib and trametinib suggest that β-catenin can positively influence cell survival also in treatment-naive V600E BRAF melanomas. This is in agreement with reports suggesting that active β-catenin signaling is associated with more aggressive melanoma and worse survival of patients. 30, 31 This also indicates that inhibition of WNT/ β-catenin signaling 17 should be considered as a part of therapy in a group of melanoma patients with elevated level of active β-catenin. We have recently demonstrated that pentoxifylline, a drug approved by the US Food and Drug Administration in the treatment of peripheral arterial disease, inhibits the activity of the canonical WNT pathway in melanoma cell populations with high basal activity of this signaling. 24 The higher percentage of slow-cycling melanoma cells retaining CFSE in the drug-treated cell populations in comparison to the control cell populations might indicate that vemurafenib and trametinib just exerted cytostatic effects. However, when these results are combined with results showing elevated expression of CD271, drug effects might be interpreted as a selection of slowly dividing melanoma stem-like cells. High level of CD271 was assessed in vemurafenib-resistant brain and lung metastasizing melanoma cells. 32 Selection of CD271-positive cells by vemurafenib in melanoma cell lines was shown to be NF-κB-dependent. 33 In another study, however, NF-κB pathway was inactive in CD271-positive melanoma cells, and was activated when this marker was lost. 34 In the present study, vemurafenib and trametinib while increasing the percentage of CD271 high cells diminished activity of NF-κB shown as reduced phosphorylation of p65 subunit and IL-8 expression. Therefore, the role of the NF-κB pathway in the regulation of CD271 needs further examination. Nevertheless, our results support the notion that slow-cycling CD271 high cells are selected by vemurafenib and trametinib, which might be a base for acquired resistance. It was recently demonstrated that CD271 (NGFR) is connected with AXL-high program, and a subset of drug-resistant melanoma biopsies exhibited increased activity of this program when compared with biopsies taken before treatment. 6 CXCL8 expression was the most significantly downregulated gene by vemurafenib and trametinib among investigated genes. IL-8 and its receptors are important for melanoma progression and metastasis. 20 CXCL8 expression is NF-κB-dependent, which is consistent with a concomitant inhibition of NF-κB activity and CXCL8 expression observed in this study. It was demonstrated in biopsies collected from patient with metastatic melanoma that treatment with either vemurafenib alone or dabrafenib in combination with trametinib was associated with reduced levels of IL-8 and IL-6. 35 Wilson et al. have shown that IL-8 is produced predominantly by ABCB5 (ATP-binding cassette, subfamily B, member 5)-negative melanoma cells comprising the bulk population. 36 Our results showing that vemurafenib and trametinib while reducing IL-8 expression increased the frequency of CD271 high /Ki-67 low cells, are in line with this notion, especially if we consider that both stem cell markers, ABCB5 and CD271 were found to be co-expressed in clinical melanoma specimens. 37 In the present study, besides IL-8 also CTGF was strongly downregulated by vemurafenib and trametinib. Lin et al. have shown that CTGF regulates CXCL8 promoter via NF-κB signaling. 38 As CTGF and CXCL8 were concomitantly downregulated by vemurafenib and trametinib, we assumed that CTGF might contribute to increased CXCL8 expression also in melanoma. However, our results revealed that CTGF neither influenced CXCL8 expression nor NF-κB activity in melanoma cells.
CTGF (CCN2) has multiple roles as oncogene and tumor suppressor in diverse cancer types. [39] [40] [41] [42] [43] [44] It is secreted and functions as a ligand of integrins, mainly αvβ3, to regulate cell proliferation, apoptosis, cell migration, angiogenesis, and anoikis. 45 Recent findings have suggested various functional implications of CTGF in melanoma development. 19, [46] [47] [48] The expression of CTGF is upregulated in advanced stages of melanoma 49 and CTGF promotes migration and invasion of melanoma cells. 46 Loss of CTGF, either in melanoma or in tumor stroma, did not affect proliferation and tumor growth but diminished the ability of melanoma cells to invade and decreased spontaneous metastases of melanoma cells from the skin to the lungs. 48 Inhibition of CTGF, either genetically or with a specific anti-CTGF monoclonal antibody (FG-3019), significantly inhibited the ability of melanoma cells to grow in the skin and establish distant metastases in the lungs of SCID mice. 19 Therefore, CTGF is considered as a therapeutic target for metastatic melanoma. Regulation of CTGF expression is complex and largely depends on the cell type and the microenvironment. 50 In melanoma, CTGF was induced by hypoxia through HIF-1-and HIF-2-dependent mechanisms. 19, 46 Our results provide initial evidence that in V600E BRAF melanoma cells, CTGF expression is ERK1/2-dependent, and therefore, can be downregulated by inhibitors of V600E BRAF and MEK1/2. It was demonstrated, however, that in three paired tumor biopsies CTGF expression was markedly upregulated after development of resistance to vemurafenib. 51 Our analysis of RNA sequencing data available at https://www.ncbi.nlm.nih.gov/geo/ revealed that changes in the CTGF expression after development of drug resistance are not so unambiguous (Supplementary Figure 3 and Supplementary Table 1 ). The development of resistance to targeted therapy (designated as progression) was accompanied by downregulated expression of CTGF in melanomas from 20 out of the 39 patients. Interestingly, all early during treatment samples expressed CTGF at lower levels than the paired drug-naive samples (Supplementary Figure 3 and Supplementary Table 1 ). Thus, clinical data although still limited and performed with diverse therapeutics targeting the RAF/MEK/ ERK pathway, support our finding on influence of targeted therapy on expression of CTGF, but also CXCL8 (Supplementary Figure 3 and Supplementary Table 1 ). By using parthenolide that simultaneously reduces NF-κB activity and induces ERK1/2 phosphorylation, it was possible to increase CTGF transcript level in melanoma cells, which further suggests that CTGF expression depends on ERK1/2 activity but not NF-κB activity. Thus, the reduced expression of CTGF was rather a consequence of the BRAF/MEK/ERK pathway inhibition than a drug off-target effect, however, further studies are necessary to elucidate the exact mechanism(s).
In summary, the present study while confirming cytostatic activity of vemurafenib and trametinib in melanoma cells also shows: (i) a drug-induced inhibition of IL-8 expression accompanied by diminished NF-κB activity; and (ii) ERK1/ 2-dependent reduction of CTGF expression. All these effects occurred despite the differences in the phenotype of investigated melanoma cell populations. The only exception was induction of apoptosis, which was triggered by vemurafenib and trametinib only in cell populations with the low level of active β-catenin. In the light of published reports about the contribution of IL-8 and CTGF to melanoma development, these newly uncovered effects of vemurafenib and trametinib are highly desired. In turn, the drug-induced expression of CD271, a marker of melanoma stem-like cells, is an unwanted consequence of targeted therapy shown in this study. Lack of response of melanoma stem-like cells to targeted therapy should be addressed in the development of combination treatment of melanoma patients, although a potent drug against cancer stem-like cells is not yet available.
Supplementary Information accompanies the paper on the Laboratory Investigation website (http://www.laboratoryinvestigation.org)
